Physician Search

Consuelo Wilkins, MD, MSCI, Senior Vice President for Health Equity and Inclusive Excellence for Vanderbilt University Medical Center (VUMC) and Senior Associate Dean for Health Equity and Inclusive Excellence for Vanderbilt University School of Medicine, always knew she wanted to be a physician. "Health equity was built into everything I did, even if I didn’t know it or recognize it at the time," Wilkins said. "I have always learned and believed that people are the same — everyone deserves to be healthy, and everyone should have the best opportunities to take care of themselves and their families." Click below to learn more about health equity initiatives.

https://momentum.vicc.org/2021/09/everyone-deserves-to-be-healthy/

Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population. Natasha Halasa, MD, MPH and colleagues recently published in the New England Journal of Medicine, that two doses of high-dose trivalent flu vaccine resulted in higher amounts of influenza-specific antibodies than two doses of standard dose quadrivalent vaccine.

https://news.vumc.org/2023/03/02/high-dose-flu-vaccine-beneficial-for-pediatric-stem-cell-transplant-patients/

Filter By:
Search by Keyword:

Displaying 31 - 40 of 73

CHAMPION -AF - WATCHMAN FLX versus NOAC for Embolic Protection in the Management of Patients with Non-Valvular Atrial Fibrillation

Disease Sites: Not Available

Phase:

Investigator: Ellis, Christopher

NCTID: NCT03795298

Protocol No: CRE-ARR0006

CSPOT - Conduction System Pacing Optimized Therapy

Disease Sites: Not Available

Phase:

Investigator: Richardson, Travis

NCTID: NCT04905290

Protocol No: CRE-ARR0007

CLASP II TR

Disease Sites: Not Available

Phase: N/A

Investigator: Barker, Colin

NCTID: NCT04097145

Protocol No: VALV0004

REPAIR MR

Disease Sites: Not Available

Phase: N/A

Investigator: Barker, Colin

NCTID: NCT04198870

Protocol No: VALV0007

ADVANTAGE-AF - A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation

Disease Sites: Not Available

Phase:

Investigator: Ellis, Christopher

NCTID: NCT05443594

Protocol No: CRE-ARR0017

A Phase 3, Multi-Center, Randomized, Double-blind Trial to Evaluate the
Efficacy and Safety of Aficamten Compared to Metoprolol in Adults with Symptomatic Obstructive
Hypertrophic Cardiomyopathy” and identified as CY 6032

Disease Sites: Not Available

Phase:

Investigator: Brinkley, Douglas

NCTID: NCT05767346

Protocol No: CRE-CHF0015

CY 6031 A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CK3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION

Disease Sites: Not Available

Phase:

Investigator: Brinkley, Douglas

NCTID: NCT05186818

Protocol No: CRE-CHF0007

The FARAPULSE ADVENT Trial

Disease Sites: Not Available

Phase:

Investigator: Ellis, Christopher

NCTID: NCT04612244

Protocol No: CRE-ARR0009

REDUCE Post Approval Study - GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO)

Disease Sites: Not Available

Phase:

Investigator: Piana, Robert

NCTID: NCT03821129

Protocol No: CRE-ARR0003

Open-Label Safety Study in Adults and Adolescents with Haemophilia A with and without FVIII Inhibitors Switching Directly from Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis

Disease Sites: Not Available

Phase: III

Investigator: Wheeler, Allison

NCTID: NCT05878938

Protocol No: NCBH2302-FRONTIER5